Related Experiment Video
Updated: Jun 20, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
[Mechanism of Modified Huoluo Xiaoling Pills against colorectal cancer based on network pharmacology, molecular
Wei Jiang1, Qiu-Ping Zhao1, Lin Huang1
1School of Clinical Medicine, Jiangxi University of Chinese Medicine Nanchang 330004, China.
Abstract:
This study aims to predict the possible targets and related signaling pathways of Modified Huoluo Xiaoling Pills against colorectal cancer(CRC) by both network pharmacology and molecular docking and verify the mechanism of action by experiments. TCMSP was used to obtain the active ingredients and targets of Modified Huoluo Xiaoling Pills, and GeneCards, DrugBank, OMIM, and TTD were employed to acquire CRC-related targets. Cytoscape software was utilized to construct the drug-active ingredient-target network, and the STRING database was applied to establish the protein-protein interaction(PPI) network. DAVID platform was adopted to investigate the targets in terms of GO function and KEGG pathway enrichment analysis. Molecular docking was performed in AutoDock Vina. HCT 116 cells were intervened by different concentrations of Modified Huoluo Xiaoling Pills-containing serum, and CCK-8 was used to detect the proliferation inhibition of HCT 116 cells in each group. Transwell was employed to show the invasive abi-lity of HCT 116 cells, and Western blot was taken to reveal the expression levels of β-catenin, cyclinD1, c-Myc, as well as epithelial-mesenchymal transition(EMT) marker proteins E-cadherin, N-cadherin, vimentin, MMP2, MMP7, MMP9, and TWIST in HCT 116 cells. The network pharmacological analysis yielded 242 active ingredients of Modified Huoluo Xiaoling Pills, 1 844 CRC targets, and 127 overlapping targets of CRC and Modified Huoluo Xiaoling Pills, and the signaling pathways related to CRC involved PI3K-Akt, TNF, HIF-1, IL-17, Wnt, etc. Molecular docking showed that the key active ingredients had a stable binding conformation with the core proteins. CCK-8 indicated that Modified Huoluo Xiaoling Pills significantly inhibited the proliferation of HCT 116 cells. Transwell assay showed that with increasing concentration of Modified Huoluo Xiaoling Pills containing serum, the invasive ability of HCT 116 cells was more obviously inhibited. The expression of β-catenin, cyclinD1, c-Myc, N-cadherin, vimentin, MMP2, MMP7, MMP9, and TWIST proteins were suppressed, and the expression of E-cadherin was improved by the intervention of drug-containing serum. Thus, it can be seen that Modified Huoluo Xiaoling Pills restrains the proliferation, invasion, and metastasis of CRC cells through multiple components, multiple targets, and multiple pathways, and the mechanism of action may be related to the inhibition of the activation of the Wnt/β-catenin signaling pathway, thereby affecting the occurrence of EMT.
Insights
Modified Huoluo Xiaoling Pills inhibit colorectal cancer (CRC) cell proliferation and invasion. This study reveals its multi-component, multi-target mechanism, potentially involving the Wnt/β-catenin pathway, offering new CRC treatment strategies.
Area of Science:
- Integrative oncology and computational pharmacology.
- Traditional Chinese Medicine (TCM) and modern drug discovery.
- Molecular biology and cancer research.
Context:
- Colorectal cancer (CRC) remains a significant global health challenge.
- Existing treatments for CRC have limitations and side effects.
- Novel therapeutic strategies targeting CRC progression are urgently needed.
Purpose:
- To elucidate the molecular mechanisms of Modified Huoluo Xiaoling Pills (MHXLP) against CRC using network pharmacology and molecular docking.
- To experimentally validate the anti-cancer effects of MHXLP on CRC cells.
- To identify key active ingredients, targets, and signaling pathways involved in MHXLP's action.
Summary:
- Network pharmacology identified 127 overlapping targets between MHXLP and CRC, implicating pathways like PI3K-Akt, TNF, HIF-1, IL-17, and Wnt.
- Molecular docking confirmed stable binding of key active ingredients to core targets.
- Experimental validation showed MHXLP significantly inhibited HCT 116 cell proliferation and invasion, downregulating Wnt/β-catenin signaling and epithelial-mesenchymal transition (EMT) markers.
Impact:
- Provides a comprehensive understanding of MHXLP's multi-component, multi-target therapeutic potential for CRC.
- Suggests MHXLP as a promising candidate for CRC treatment, potentially through Wnt/β-catenin pathway inhibition.
- Highlights the synergy of computational and experimental approaches in validating TCM-based therapies.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023